熱門資訊> 正文
Cidara裁员30%，专注于CD 388治疗流感
2024-09-13 05:14
- Cidara Therapeutics (NASDAQ:CDTX) said it was cutting around 30% of its workforce to focus resources on its drug-Fc conjugate candidate CD388 for the prevention of influenza A and B.
- The company added it was still in business development discussions for its oncology drug-Fc conjugate programs, which includes CBO421. The drug candidate recently received clearance from the FDA to begin a Phase 1 study, according to a statement.
More on Cidara Therapeutics
- Cidara Therapeutics files for 16.8M common stock offering
- Seeking Alpha’s Quant Rating on Cidara Therapeutics
- Historical earnings data for Cidara Therapeutics
- Financial information for Cidara Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
